Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 88 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Post-Lung Transplantation Clear all
Terminated Phase 4 Interventional Results available

Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment

NCT03207399
View directory record Official record
Conditions
Hepatitis C, Chronic, Lung Transplant
Interventions
Epclusa
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Jul 23, 2026, 2:12 PM EDT
Recruiting Not applicable Interventional

Intercostal Cryoanalgesia in Double Lung Transplant Recipients

NCT07281118
View directory record Official record
Conditions
Post-operative Pain Management
Interventions
Atricure CryoSPHERE MAX Probe
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Waco, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Phase 4 Interventional Results available

Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.

NCT01808456
View directory record Official record
Conditions
Influenza, Human, Transplantation Infection
Interventions
influenza trivalent inactive vaccine, influenza trivalent inactive vaccine high dose
Biological
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Rituximab for Prevention of Chronic GVHD

NCT00379587
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Rituximab, 375 mg/m2 RRituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant

NCT01559844
View directory record Official record
Conditions
Hepatitis C, Hepatocellular Carcinoma
Interventions
Sofosbuvir, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Respiratory Syncytial Virus - RSV Protocol

NCT01502072
View directory record Official record
Conditions
Bone Marrow Transplant Infection, Infection in Marrow Transplant Recipients, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Pneumonia, Cancer, Acute Leukemia
Interventions
Ribavirin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2021 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

Lung Transplant Subjects Using 19F MRI

NCT02019251
View directory record Official record
Conditions
Post Single or Double Lung Transplant
Interventions
perfluorinated gas/oxygen mixture, MRI
Drug · Device
Lead sponsor
Hal C Charles
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

Use of Busulfan as Conditioning Agent for a Second Stem Cell Transplant

NCT00092937
View directory record Official record
Conditions
Granulomatous Disease, Chronic
Interventions
Busulfan
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 2:12 PM EDT
Recruiting No phase listed Observational

The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)

NCT05250037
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Home spirometry, Biospecimen Collection, Questionnaire Administration
Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
8 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Ann Arbor, Michigan • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 23, 2026, 2:12 PM EDT
Recruiting Not applicable Interventional

A Study of Latin Dance for Post- Lung Transplant

NCT05924113
View directory record Official record
Conditions
Lung Transplant, Well-Being, Psychological
Interventions
Latin Dance
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients

NCT02351180
View directory record Official record
Conditions
Lung Transplant Infection
Interventions
Inhaled beclomethasone, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation

NCT00227370
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
valganciclovir, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

The Safety and Tolerability of Pirfenidone for BOS After HCT

NCT03315741
View directory record Official record
Conditions
Bronchiolitis Obliterans, Graft Vs Host Disease
Interventions
Pirfenidone 267 MG [Esbriet]
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2022 · Synced Jul 23, 2026, 2:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Influenza Vaccine in Lung Transplant Patients

NCT00205270
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Not applicable Interventional Results available

Lung Transplant G0 (LTGO): Improving Self-Management of Exercise After Lung Transplantation

NCT03728257
View directory record Official record
Conditions
Exercise, Lung Transplantation
Interventions
LTGO-Home Based Exercise, Enhanced Usual Care
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Jul 23, 2026, 2:12 PM EDT
Completed No phase listed Observational

Factors Predicting Success in Lung Transplant Recipients Who Have Undergone Intensive Post-operative Rehabilitation

NCT03299504
View directory record Official record
Conditions
Lung Transplant
Interventions
Exercise
Other
Lead sponsor
Indiana University Health Methodist Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Jul 23, 2026, 2:12 PM EDT
Recruiting Phase 3 Interventional

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

NCT06615050
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux), Cyclophosphamide, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
30
States / cities
Palo Alto, California • San Francisco, California • Miami, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 23, 2026, 2:12 PM EDT
Terminated Phase 1 Interventional

Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant

NCT04239989
View directory record Official record
Conditions
Bronchiolitis Obliterans
Interventions
Itacitinib, Itacitinib Adipate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Phase 4 Interventional Results available

Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS)

NCT01469364
View directory record Official record
Conditions
Complication of Transplanted Lung
Interventions
Aztreonam Lysine for Inhalation (AZLI), Status Post Lung Transplant
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Los Angeles, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

NCT02759731
View directory record Official record
Conditions
Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease
Interventions
Baricitinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Jul 23, 2026, 2:12 PM EDT
Completed No phase listed Observational

CLAD Phenotype Specific Risk Factors and Mechanisms

NCT02631720
View directory record Official record
Conditions
Lung Transplant, Post Lung Transplantation
Interventions
Blood Draw, Bronchoscopy
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 23, 2026, 2:12 PM EDT
Terminated No phase listed Observational

Early Indicators of Chronic Rejection in Lung Transplant

NCT00449332
View directory record Official record
Conditions
Chronic Rejection in Lung Transplant, Cytokine Production in Bos Post Lung Transplant
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Jul 23, 2026, 2:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients

NCT01650545
View directory record Official record
Conditions
Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity, Chronic Rejection of Lung Transplant
Interventions
Liposomal aerosol cyclosporine, standard immune suppression, oral
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Jul 23, 2026, 2:12 PM EDT
Completed No phase listed Observational

Voriconazole Prophylaxis Against Aspergillosis in Lung Transplant Recipients

NCT00177827
View directory record Official record
Conditions
Post Lung Transplantation
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Jul 23, 2026, 2:12 PM EDT